- Home
- IGMS vs PSTL Comparison
IGMS vs PSTL Comparison
Compare IGMS & PSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- PSTL
- Stock Information
- Founded
- IGMS 1993
- PSTL 2018
- Country
- IGMS United States
- PSTL United States
- Employees
- IGMS N/A
- PSTL N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- PSTL Real Estate Investment Trusts
- Sector
- IGMS Health Care
- PSTL Real Estate
- Exchange
- IGMS Nasdaq
- PSTL Nasdaq
- Market Cap
- IGMS 348.5M
- PSTL 303.8M
- IPO Year
- IGMS 2019
- PSTL 2019
- Fundamental
- Price
- IGMS $1.77
- PSTL $13.05
- Analyst Decision
- IGMS Hold
- PSTL Strong Buy
- Analyst Count
- IGMS 8
- PSTL 1
- Target Price
- IGMS $6.14
- PSTL $15.50
- AVG Volume (30 Days)
- IGMS 779.9K
- PSTL 173.1K
- Earning Date
- IGMS 03-06-2025
- PSTL 02-24-2025
- Dividend Yield
- IGMS N/A
- PSTL 7.36%
- EPS Growth
- IGMS N/A
- PSTL N/A
- EPS
- IGMS N/A
- PSTL 0.08
- Revenue
- IGMS $2,918,000.00
- PSTL $72,005,000.00
- Revenue This Year
- IGMS $23.57
- PSTL N/A
- Revenue Next Year
- IGMS $192.36
- PSTL $11.60
- P/E Ratio
- IGMS N/A
- PSTL $164.37
- Revenue Growth
- IGMS 57.64
- PSTL 16.87
- 52 Week Low
- IGMS $1.59
- PSTL $12.43
- 52 Week High
- IGMS $22.50
- PSTL $15.15
- Technical
- Relative Strength Index (RSI)
- IGMS 19.54
- PSTL 47.12
- Support Level
- IGMS $1.59
- PSTL $12.43
- Resistance Level
- IGMS $2.06
- PSTL $13.11
- Average True Range (ATR)
- IGMS 0.45
- PSTL 0.22
- MACD
- IGMS -0.30
- PSTL 0.06
- Stochastic Oscillator
- IGMS 3.27
- PSTL 83.40
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.